Literature DB >> 27139162

Variation of glucose tolerance in adult patients with cystic fibrosis: What is the potential contribution of insulin sensitivity?

Valérie Boudreau1, Adèle Coriati2, Imane Hammana3, Sophie Ziai4, Katherine Desjardins5, Yves Berthiaume6, Rémi Rabasa-Lhoret7.   

Abstract

BACKGROUND: Reduced insulin secretion is a key factor to explain high prevalence of glucose intolerance in patients with cystic fibrosis (CF). However, the role of insulin sensitivity remains unclear. The aim of this study is to investigate the association of insulin secretion and sensitivity with the evolution of glucose tolerance.
METHODS: A total of 152 patients without known diabetes from the Montreal CF cohort underwent two 2-h oral glucose tolerance tests (OGTT) at baseline and again after 21.2±5.5months. Pulmonary function and anthropometric measurements were also collected at each visit. At both visits, based on their OGTT results, patients were categorized in glucose tolerance groups (normal glucose tolerance, impaired glucose tolerance or CF-related diabetes) and stratified in 3 groups according to the variation of their glucose tolerance: stable, improved or deteriorated.
RESULTS: At baseline, patients in the deteriorated group had a better sensitivity to insulin than those in the improved group (P=0.029). At follow-up glucose tolerance remained stable in 55.3%, improved in 14.5% and deteriorated in 30.3% of patients. During follow-up, insulin secretion remained stable in all 3 groups. While insulin sensitivity remained stable in patients without changes in glucose tolerance it worsened in patients who deteriorated glucose tolerance (P<0.001) and improved in patients who improved their glucose tolerance (P=0.003).
CONCLUSION: In a context of significantly reduced insulin secretion, variations of insulin sensitivity are associated with variations of glucose tolerance in adult patients with CF. Copyright Â
© 2016 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Adult; CFRD; Cystic fibrosis; Insulin sensitivity; Oral glucose tolerance test

Mesh:

Substances:

Year:  2016        PMID: 27139162     DOI: 10.1016/j.jcf.2016.04.004

Source DB:  PubMed          Journal:  J Cyst Fibros        ISSN: 1569-1993            Impact factor:   5.482


  11 in total

1.  Associations Between Glucose Tolerance, Insulin Secretion, Muscle and Fat Mass in Cystic Fibrosis.

Authors:  Bibi Uhre Nielsen; Daniel Faurholt-Jepsen; Peter Sandor Oturai; Tavs Qvist; Rikke Krogh-Madsen; Terese Lea Katzenstein; James Shaw; Christian Ritz; Tacjana Pressler; Thomas Peter Almdal; Inger Hee Mabuza Mathiesen
Journal:  Clin Med Insights Endocrinol Diabetes       Date:  2021-08-13

2.  Cystic fibrosis-related diabetes onset can be predicted using biomarkers measured at birth.

Authors:  Yu-Chung Lin; Katherine Keenan; Jiafen Gong; Naim Panjwani; Julie Avolio; Fan Lin; Damien Adam; Paula Barrett; Stéphanie Bégin; Yves Berthiaume; Lara Bilodeau; Candice Bjornson; Janna Brusky; Caroline Burgess; Mark Chilvers; Raquel Consunji-Araneta; Guillaume Côté-Maurais; Andrea Dale; Christine Donnelly; Lori Fairservice; Katie Griffin; Natalie Henderson; Angela Hillaby; Daniel Hughes; Shaikh Iqbal; Jennifer Itterman; Mary Jackson; Emma Karlsen; Lorna Kosteniuk; Lynda Lazosky; Winnie Leung; Valerie Levesque; Émilie Maille; Dimas Mateos-Corral; Vanessa McMahon; Mays Merjaneh; Nancy Morrison; Michael Parkins; Jennifer Pike; April Price; Bradley S Quon; Joe Reisman; Clare Smith; Mary Jane Smith; Nathalie Vadeboncoeur; Danny Veniott; Terry Viczko; Pearce Wilcox; Richard van Wylick; Garry Cutting; Elizabeth Tullis; Felix Ratjen; Johanna M Rommens; Lei Sun; Melinda Solomon; Anne L Stephenson; Emmanuelle Brochiero; Scott Blackman; Harriet Corvol; Lisa J Strug
Journal:  Genet Med       Date:  2021-01-26       Impact factor: 8.822

Review 3.  Evolving Mechanistic Views and Emerging Therapeutic Strategies for Cystic Fibrosis-Related Diabetes.

Authors:  John C Yoon
Journal:  J Endocr Soc       Date:  2017-10-30

4.  Glucose tolerance in Canadian and French cystic fibrosis adult patients.

Authors:  Quitterie Reynaud; Valérie Boudreau; Sandrine Touzet; Katherine Desjardins; Stéphanie Poupon Bourdy; Emilie Blond; Yves Berthiaume; Rémi Rabasa-Lhoret; Isabelle Durieu
Journal:  Sci Rep       Date:  2019-03-18       Impact factor: 4.379

5.  Effects of aerobic interval training on glucose tolerance in children and adolescents with cystic fibrosis: a randomized trial protocol.

Authors:  Karolinne Souza Monteiro; Matheus de Paiva Azevedo; Lucas Menescal Jales; Fernanda Elizabeth Pereira da Silva; Ricardo Fernando Arrais; Karla Morganna Pereira Pinto de Mendonça
Journal:  Trials       Date:  2019-12-26       Impact factor: 2.279

Review 6.  Cystic Fibrosis-Related Diabetes (CFRD): Overview of Associated Genetic Factors.

Authors:  Fernanda Iafusco; Giovanna Maione; Francesco Maria Rosanio; Enza Mozzillo; Adriana Franzese; Nadia Tinto
Journal:  Diagnostics (Basel)       Date:  2021-03-22

7.  The role of genetic modifiers, inflammation and CFTR in the pathogenesis of Cystic fibrosis related diabetes.

Authors:  Sana Hasan; Sarah Soltman; Colleen Wood; Scott M Blackman
Journal:  J Clin Transl Endocrinol       Date:  2021-12-10

Review 8.  The Potential Causes of Cystic Fibrosis-Related Diabetes.

Authors:  Lise Coderre; Lyna Debieche; Joëlle Plourde; Rémi Rabasa-Lhoret; Sylvie Lesage
Journal:  Front Endocrinol (Lausanne)       Date:  2021-07-30       Impact factor: 5.555

9.  Characterization of glucose metabolism in youth with vs. without cystic fibrosis liver disease: A pilot study.

Authors:  Maria Socorro Rayas; Kara S Hughan; Rida Javaid; Andrea Kelly; Marzieh Salehi
Journal:  J Clin Transl Endocrinol       Date:  2022-03-21

10.  Peak glucose during an oral glucose tolerance test is associated with future diabetes risk in adults with cystic fibrosis.

Authors:  Anne Bonhoure; Kathryn J Potter; Johann Colomba; Valérie Boudreau; Cindy Bergeron; Katherine Desjardins; Maïté Carricart; François Tremblay; Annick Lavoie; Rémi Rabasa-Lhoret
Journal:  Diabetologia       Date:  2021-03-11       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.